News

RTsafe announces first use of its PseudoPatient patient-specific quality assurance process by Fundación Instituto Valenciano de Oncología (IVO)

13February 2023

 

Athens, Greece, February 13, 2023  

RTsafe, the leading provider of quality assurance products and services in stereotactic radiosurgery, announces that Spain’s Fundación Instituto Valenciano de Oncología (IVO) has conducted its first simulated therapy for brain metastases using PseudoPatient, RTsafe’s patient-specific quality assurance process that comprises an anatomically faithful model of each patient’s head aligned to dosimetric evaluation services. The technology enables medical physicists and clinicians to verify the entire treatment process before the actual patient is subjected to radiotherapy.

Commenting on the announcement, Evangelos Pappas, Founder and Chief Scientific Officer at RTsafe said:

“We are delighted that IVO, Spain’s internationally renowned centre of excellence in cancer treatment, has embraced the concept of assuring patient safety and treatment efficiency through human-like simulation of the stereotactic radiosurgery process.”

The simulation was carried out ahead of IVO’s first patient treatment using the new TrueBeam linear accelerator from Varian Medical Systems, a Siemens Healthineers company, that integrates radiotherapy and image-guided radiosurgery on the same platform. The machine was acquired as part of the ongoing efforts by IVO’s Radiation Oncology Service to increase patient safety and treatment quality. A case study published by medical technology distribution company, Aplicaciones Tecnológicas de la Física, points out that due to the complexity of administering SRS plans, periodic quality control protocols and pre-treatment dose verification procedures based on the actual patient anatomy are advisable and could improve treatment efficiency.

The PseudoPatient treatment verification process begins with the construction of a 3D-printed phantom based on the individual patient’s CT scan accurately reproducing the bone anatomy. The phantom is then filled with a special polymer gel developed by RTsafe that acts as both a soft tissue equivalent material and a 3D dosimeter. The end-to-end radiosurgery procedure is then performed just as it would be on the real patient. The irradiated phantom is then MRI scanned and changes in gel’s magnetic properties reveal the treated areas. RTsafe then provides a comprehensive quantitative and qualitative report in order to assist the clinical team in either verifying the treatment plan or making adjustments to it.

Conventional patient-specific quality control methods involve dose measurements on a standard-shaped phantom equipped with several detectors with the aim of verifying the treatment plan. However, dose treatment verification based on the actual patient anatomy may be critical in minimising unwanted exposure to radiation. RTsafe’s development of PseudoPatient seeks to solve the limitations presented by generic phantoms thereby achieving more rigorous quality control in stereotactic radiosurgery (SRS) treatments.

Evangelos Pappas added:

“Brain metastases can occur in more than 30% of all cancer patients and, while SRS is a good treatment option for many patients, its complexity means that accurate pre-treatment dose verification could make a difference to treatment outcomes should an adjustment to dosage or targeting be indicated by the simulation process. The approach improves the confidence of both medical professionals and patients in this exacting treatment method.”

Read the full case study here: http://bit.ly/3i1Lxp7.

 Press to download the Press Release

 

About RTsafe

RTsafe is a medical technology company that has developed a unique approach to quality assurance that is making a contribution to the safety and accuracy of radiotherapy for cancer and other medical conditions. It combines proven expertise in medical physics with highly accurate 3D printing technology to create pseudo‐in‐vivo dosimetry phantoms for use in end‐to‐end commissioning, benchmarking, and patient‐specific quality assurance in stereotactic radiotherapy. The anatomically accurate effigies enable medical professionals to simulate therapeutic interventions for each patient ahead of actual treatment and help radiotherapy technology innovators to verify the performance of their products. See www.rt-safe.com.

About IVO

The Valencian Institute of Oncology Foundation (IVO) is a private, non-profit entity, whose assets and resources are devoted entirely to the fight against cancer in all its aspects: prevention, diagnosis, treatment, research and teaching. With more than 40 years of experience, the IVO is recognized nationally and internationally as a reference center in oncology. In 2021, IVO has been distinguished among the 50 best cancer hospitals in the world by Newsweek magazine. See www.ivo.es

About Aplicaciones Tecnológicas de la Física

Aplicaciones Tecnológicas de la Física is a Spanish technological company dedicated mainly to the distribution of medical technology in the field of radiotherapy, and radiological protection. We have more than 35 years of experience and strong technical and sales capabilities. See www.atfisica.com

For further information please contact: Prof. Evangelos Pappas | +30 210 7563691 | [email protected]

Explore our Products
& Services
  • 11April 2024

    RTsafe to exhibit at ISRS Congress 2024 in New York, USA

    Read More
  • 03April 2024

    RTsafe and the Spanish Radiosurgery Society (SER) signed a strategic partnership agreement towards optimizing Stereotactic Radiosurgery treatment quality in Spain 

    Read More

Request a quote

ΕΣΠΑ Banner